CSPC Pharmaceutical Group and AstraZeneca have entered into a joint venture contract to build a new-generation biologics manufacturing facility in Shijiazhuang, China.

The venture marks the third strategic agreement the two companies have struck in as many years, and is expected to focus on the manufacturing and supply of mutually agreed biologics drug substances for global markets, with the companies contributing capital at a 51:49 equity ratio in favor of CSPC.¹

The deal builds on AstraZeneca’s continued investment in research and development deals in China.

What are the terms of the joint venture?

Under the terms of the joint venture contract, CSPC and AstraZeneca will jointly manage construction along with day-to-day operations, drawing on their respective strengths. As the business develops, production capacity scales up, and commercial demand grows, the companies say they will explore incorporating additional products into the joint venture's scope.¹

The agreement remains subject to customary closing conditions, including regulatory approvals.

The joint venture is designed to combine CSPC's AI-driven Good Manufacturing Practice system and its pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management.¹ The initial business scope centers on biologics drug substances, with both companies committing to delivering high-quality medicines to patients worldwide.

Why does this matter for CSPC's global ambitions?

CSPC says the collaboration reflects strong recognition of its modernized manufacturing system, quality management capabilities, and industrial-scale execution by a leading global multinational pharmaceutical company. The company frames the joint venture as extending its internationalization path from "going global with products and technologies" to "going global with manufacturing systems and supply chain capabilities."¹

As global pharmaceutical companies continue to optimize research, manufacturing, and supply chain footprints, CSPC argues that high-quality, efficient, and sustainable manufacturing and supply capabilities are becoming a core competency across the global innovative drug value chain, laying groundwork for more of its innovative drug products to enter international markets.

Previous deals between CSPC and AstraZeneca

The manufacturing joint venture builds on a fast-deepening relationship between the two companies. In June 2025, AstraZeneca and CSPC entered a strategic research collaboration to discover and develop pre-clinical oral candidates against high-priority targets across multiple chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases.² The research is being carried out by CSPC in Shijiazhuang using its AI-driven, dual-engine drug discovery platform. As part of the agreement, CSPC received an upfront payment of $110 million and eligiblity for up to $1.62 billion in development milestone payments and upwards of $3.6 billion in sales milestone payments.²

More recently, the companies struck a collaboration to advance next-generation therapies for obesity and type 2 diabetes across eight programs, four of which will progress initially using CSPC's AI-driven peptide drug discovery platform and its proprietary LiquidGel once-monthly dosing technology.³ AstraZeneca secured exclusive global rights outside China to CSPC's once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical programs.³

What comes next?

With the biologics manufacturing joint venture still pending regulatory clearance, CSPC says it believes the new facility will strengthen its ability to meet international manufacturing and supply demand while supporting the broader pipeline of products emerging from its expanding partnership with AstraZeneca.

Sources

1. Entering Into a Joint Venture Contract With AstraZeneca in Relation to the Establishment of a Joint Venture to Further Deepen Strategic Collaboration CSPC Pharmaceutical Group Limited August 5, 2026, https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0805/2026080500460.pdf
2. AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research AstraZeneca June 13, 2025 https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html
3. AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals AstraZeneca January 30, 2026, https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-agrees-obesity-and-t2d-deal-with-cspc.html